We retrospectively reviewed medical records of 39 hematopoietic SCT (HSCT) recipients who presented at our hospital between 1 October 2009 and 31 January 2010 with the 2009 H1N1 influenza infection. The median age at presentation was 13.8 years (range: 3.3-56.9), infections developed at a median of 585 days (range: 0-2316) post transplant, the majority (n ¼ 27, 69%) occurred in allogeneic HSCT recipients, 12 (31%) patients were on immunosuppressive therapy and 12 (31%) had GVHD. Lower airway disease was present in 8 patients (21%). In total, 15 patients (39%) were hospitalized with a median duration of 4.5 days (range: 3-27 days) and 3 (8%) required mechanical ventilation; 2 of whom died.
Introduction
Infections with the 2009 H1N1 virus among the general population have been characterized as being generally mild with a severity similar to that reported for seasonal influenza infections. 1, 2 However, several risk factors have been reported as being associated with either severe clinical courses or detrimental outcomes. These factors include obesity, chronic lung disease, chronic heart disease, chronic renal disease, diabetes mellitus, neuro-developmental disorders, pregnancy, certain age groups and severe immunosuppression. [3] [4] [5] [6] [7] [8] [9] Previous studies have shown that seasonal influenza infections among recipients of hematopoietic SCT (HSCT) had been linked to a higher incidence of lower airway disease, respiratory failure and high mortality. [10] [11] [12] [13] [14] [15] Our present knowledge about the 2009 H1N1 influenza among recipients of HSCT, however, is still limited; early reports have indicated a potential for increased morbidity and mortality among recipients of HSCT with the 2009 H1N1 influenza. 16, 17 Jordan reported the first two cases of the 2009 H1N1 influenza on 17 June 2009. Yet it was not until 28 September 2009, when the first case of the 2009 H1N1 influenza was documented at King Hussein Cancer Center (KHCC). A BM and SCT unit was established at the center in 2002 18 with 80 transplants being performed per year on average. As of 31 January 2010, 339 patients were being actively followed at KHCC; 215 had received allogeneic grafts (150 pediatric and 65 adult patients) and 120 had received autologous grafts (21 pediatric and 99 adult patients).
This current study was conducted to gain better understanding of the clinical presentations and outcomes of the 2009 H1N1 influenza among recipients of HSCT diagnosed at KHCC in Amman, Jordan, during the peak of the pandemic.
Patients and methods

Patient information and settings
Institutional Review Board approval was obtained before initiating the study. HSCT recipients who were tested for the 2009 H1N1 virus were identified from the infection control records; the infection control program had developed a daily updated database for all patients who were tested for the 2009 H1N1 virus by the reverse transcriptase PCR (RT-PCR) test. Open chart review was conducted to collect further information on the study patients, including demographics, clinical presentations, transplant characteristics, treatment received and outcomes. Potential candidate risk factors for the development of severe infection were investigated. These included primary disease, type of transplantation (autologous vs allogeneic), presence of GVHD, immunosuppressive therapy, presence of comorbid conditions, mode of acquisition (health care associated vs community acquired), obesity (body mass index X30 kg/m 2 ), lymphopenia and neutropenia.
Definitions
Infections with the 2009 H1N1 influenza virus were classified as health care-associated if the signs and symptoms of the infection became evident X48 h after hospital admission. Otherwise, they were classified as communityacquired. Hypoxemia was defined as an oxygen saturation o92% on room air as measured by an arterial blood gas sample or pulse oximetry of a well-perfused digit at room temperature. Lymphopenia was defined as an absolute lymphocyte count (ALC) o1000 cells/mL, mild lymphopenia was defined as an ALC of 201-999 cells/mL, severe lymphopenia was defined as an ALC p200 cells/mL and neutropenia was defined as an ANC o500 cells/mL. Acute respiratory failure was defined as any impairment in oxygenation or ventilation in which the arterial oxygen tension falls below 60 mm Hg (acute hypoxemia), the carbon dioxide tension rises above 50 mm Hg (acute hypercarbia and hypercapnia) and the pH drops below 7.35, or both.
19 H1N1-related mortality was defined as a death in a patient with an illness clinically compatible with influenza and whose influenza is laboratory-confirmed. 20 Attack rate was defined as the number of exposed patients infected with the 2009 H1N1 virus divided by the total number of exposed HSCT recipients. Case-fatality rate was defined as the ratio of deaths among HSCT recipients who were infected with the 2009 H1N1 influenza.
Infection control measures and treatment
The infection control program at KHCC responded to the evolving 2009 H1N1 pandemic by developing guidelines and strategies to prepare the institution to cope with the possibility of a large number of KHCC patients being infected with the 2009 H1N1 influenza. Guidelines were developed in accordance with the CDC guidelines and recommendations. [21] [22] [23] The guidelines focused on two aspects: infection prevention and management of infected patients. The infection prevention aspect of the guidelines included developing a comprehensive preparedness plan, re-emphasizing the basic elements of infection control measures (for example, hand hygiene and cough etiquette) among staff and patients, allocating special negativepressure isolation rooms to accommodate the 2009 H1N1 infected patients, limiting visitation at KHCC, canceling all social activities inside the center and assuring the availability of all medical supplies (for example, N95 respirators and Oseltamivir). The management aspect of the guidelines, on the other hand, focused on early identification and triaging of patients with upper respiratory symptoms and early initiation (that is, within 24 h of the first encounter) of antiviral therapy for patients with probable 2009 H1N1 influenza. Furthermore, the guidelines enlisted the indications to test for the 2009 H1N1 virus by RT-PCR; this included the presence of influenza-like illness in any HSCT recipient. The indications for hospital admission included HSCT recipients who are on or have been on immunosuppressive therapy in the 6 months before diagnosis, those with evidence of lower airway disease, extremes of ages (o2 and more than 65 years) and the presence of chronic medical conditions. In addition, the guidelines outlined the indications for the use of antiviral therapy for treatment; these included HSCT recipients with a clinical picture compatible with the 2009 H1N1 influenza, patients who fulfilled the admission criteria for suspected 2009 H1N1 influenza and patients who had a positive RT-PCR test and/or rapid Ag test. Oseltamivir, at the usual therapeutic doses according to age and weight, was selected to be the treatment of choice for patients with suspected or confirmed infections. 24 Finally, the guidelines identified three groups of high-risk patients for whom the duration of oseltamivir therapy was extended to 10 days; this included autologous HSCT recipients until 1 year post transplant and all pediatric patients o2 years of age. The third group included allogeneic HSCT recipients on immunosuppressive therapy until they are off such therapy for at least 6 months (that is, a minimum of 1 year post-allogeneic HSCT).
RT-PCR technique
The 2009 H1N1 virus was detected by using real-time RT-PCR assays according to the protocol from the US Centers for Disease Control and Prevention, as recommended by the World Health Organization. 25 Characteristics of HSCT recipients with the 2009 H1N1 influenza A total of 39 HSCT recipients were diagnosed with the 2009 H1N1 influenza; 27 were males with a median age of 13.8 years (range: 3.3-56.1 years). The characteristics of the HSCT recipients with the 2009 H1N1 influenza are described in Table 2 . The median duration from transplantation to the development of the 2009 H1N1 infection was 585 days (range: 0-2316 days); 6 patients (15%) were infected in the first 100 days post transplant whereas the rest (33 patients, 85%) were infected X100 days after receiving their transplant. The median time from symptoms to the start of therapy was 1 day (range: 1-22 days). GVHD had been diagnosed in 12 (31%) patients before the development of the 2009 H1N1 infection: 3 patients were diagnosed with acute GVHD, 2 had skin involvement and 1 had multisystem involvement; whereas 9 were diagnosed with chronic GVHD, 5 had multisystem, 3 had skin involvement and 1 had lung involvement. In total, 12 patients (31%) were on immunosuppressive therapy at the time of the diagnosis of the infection; 8 patients were receiving corticosteroids, whereas 6 of the 12 were on two or more immunosuppressive agents. In all, 17 patients (44%) had comorbid conditions (1-4 comorbid conditions per patient; median 1). The comorbid conditions were reactive airway disease ( Figure 1 Clinical course of all recipients of HSCT who were diagnosed with the 2009 H1N1 influenza during the pandemic. obstructive sleep apnea (n ¼ 1). Of note, 1 patient was a kidney transplant recipient and another had history of bronchiolitis obliterans; 7 (18%) patients were obese with a body mass index X30 kg/m 2 ; 1 (3%) patient had severe lymphopenia, 12 (31%) had mild lymphopenia, 1 had hypogammaglobulinemia (serum IgG o500 mg/dL) and none had neutropenia at the time of diagnosis. In total, 6 (15%), 23 (59%) and 1 (3%) patient had received the seasonal influenza, the pneumococcal polysaccharide and the conjugated pneumococcal vaccines, respectively, before they developed the 2009 H1N1 influenza.
Results
Patients presenting with influenza symptoms
n ¼ 3), splenectomy (n ¼ 3), hypo- thyroidism (n ¼ 3), hypertension (n ¼ 4), ischemic heart disease (n ¼ 1), diabetes mellitus (n ¼ 2), hyperlipidemia (n ¼ 1), common
Treatment and outcomes
All patients with probable 2009 H1N1 influenza were treated empirically with the age-and weight-adjusted doses of oseltamivir in accordance with the pre-developed guidelines. Among the patients with the 2009 H1N1 influenza, the median duration of treatment was 7 days (range: 0-10 days). One patient, who was 28 months post-HSCT and 5 months off immunosuppression, was inadvertently not treated with oseltamivir or any other antiviral therapy for the 2009 H1N1 influenza. A total of 24 (62%) patients were clinically stable, did not meet the admission criteria and were treated as outpatients. In all, 15 (39%) patients were hospitalized (Table 3. ); 12 (31%) met the preset admission criteria whereas 3 (8%) patients acquired the infection during their hospitalization for other indications. Of the 15 patients who were hospitalized, 8 (53%) were recipients of allogeneic HSCT whereas 7 (47%) were recipients of autologous HSCT; 8 (53%) patients were children whereas 7 (47%) were adults. The median duration of hospital stay was 4.5 days (range: 3-27 days) from the time of diagnosis. All patients who were treated as outpatients and 12 out of the 15 hospitalized patients recovered completely without complications (36 out of 39 patients); symptoms resolved within 1-14 days after initiating antiviral therapy (median 1.5 days). A total of 28 patients had chest radiographs performed; lower airway disease was present in 8 (29%) patients (confirmed by chest computed tomography scan in 4) and 6 of them were hospitalized. Of the patients with radiologically confirmed lower airway disease, 5 were lymphopenic, 4 were receiving corticosteroids and 7 had other comorbid conditions. Out of the 11 patients who did not have chest radiographs done, none subsequently developed a severe disease (that is, respiratory failure requiring assisted ventilation) nor required admission.
Lymphopenia was documented in 13 patients (33%; 5 children and 8 adults). The 1 patient who had severe lymphopenia died after developing respiratory failure; 3 had an ALC of 201-499 cells/mL, 2 of whom developed respiratory failure and 1 died; and 9 had an ALC of 500-999 cells/mL, 4 of whom were hospitalized, but none developed severe disease nor died. In total, 8 (53%) of the hospitalized patients, 2 of those with respiratory failure (67%) and 1 of the 2 who died (50%) were receiving immunosuppressive therapy (Table 3) .
In total, 3 of the 15 (20%) hospitalized patients developed respiratory failure and 2 of them died (overall case fatality rate was 5%). Causes of death included acute respiratory distress syndrome and viral pneumonia (1 patient was coinfected with Stenotrophomonas maltophilia). All patients who required hospitalization and had a mild disease were in the hospital for o7 days whereas patients who developed respiratory failure were hospitalized for longer durations. None of the patients developed neurologic complications before or after treatment. Of note, 1 patient with the 2009 H1N1 influenza, who required mechanical ventilation, but later recovered, had documented bacterial pneumonia with a multi-drug resistant Acinetobacter baumannii and a multi-drug resistant Pseudomonas aeruginosa before he developed respiratory failure. It is also worth mentioning that the patient who was inadvertently not treated for the 2009 H1N1 influenza recovered completely without complications. Table 3 The clinical presentations for most patients in our study were similar to those of seasonal influenza, a finding also observed by others. 26, 27 Cough and fever were the most common symptoms observed in our patients. This is comparable with the 2009 H1N1 influenza presentation in the general population in whom fever and cough were the most common presenting symptoms. 7, 26, 28 Lower airway disease was observed in 8 out of 28 (29%) patients who had chest radiographs done, 4 of which were confirmed by chest computed tomography scan; a finding similar to that reported in the first case series of the 2009 H1N1 influenza in cancer and HSCT recipients. 27 Initial case reports have shown a severe disease among recipients of HSCT. 16, 17 In our series, 31 (79%) patients had an uneventful course of the disease and recovered completely without complications, 8 (21%) had lower airway disease, 3 (8%) developed respiratory failure requiring mechanical ventilation and 2 (5%) patients died. Redelman-Sidi et al. 27 reported their experience with the 2009 H1N1 influenza in cancer patients and HSCT recipients. Of 394 cancer patients (including 96 HSCT recipients) tested, 45 (11%) were diagnosed with the 2009 H1N1 influenza, 21 of whom were HSCT recipients. In all, 8 (27%) patients had lower airway disease, 17 (37%) were hospitalized and none died or required mechanical ventilation.
The proportion of HSCT recipients with positive tests for the 2009 H1N1 influenza was 22% (21/96). No deaths were associated with the 2009 H1N1 influenza in their cohort. The reasons for the favorable outcome observed in the majority of patients in our study and also reported by Redelman-Sidi et al. is not well understood; it may be partly explained by the prompt initiation of antiviral therapy in suspected cases as has been suggested by previous studies. 8, 15 Mortality rates associated with seasonal influenza A in recipients of HSCT, on the other hand, varied among different series and ranged from 0 up to 25%. 14, 15, 29, 30 Furthermore, earlier studies of the outcomes of the 2009 H1N1 infections that included patients with different underlying diseases, have reported high overall mortality rates among hospitalized and critically ill patients. 5, 6, 9 More recently, a review of the 2009 H1N1 influenza indicated an overall case fatality rate o0.5%.
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Factors that render patients at higher risk of complications and mortality from the 2009 H1N1 influenza in recipients of HSCT are not well defined yet. In our cohort, lymphopenia was present in 5 (63%) patients with lower airway disease and in 6 (75%) of those with lower airway disease who were hospitalized. Moreover, respiratory failure and deaths were only observed in patients with lymphopenia, whereas none occurred in those with an ALCX1000. The incidence of severe lymphopenia in our study was unexpectedly low despite the fact that 12 (31%) patients had GVHD and were receiving immunosuppresssive therapy (half of them were on two or more immunosuppressive agents). This low rate of lymphopenia may be attributed to the fact that most (9 of the 12) patients with GVHD had chronic GVHD and were maintained on small doses of immunosuppressive agents; these low doses are not expected to cause severe lymphopenia. Nonetheless, lymphopenia was present in the majority of radiologically confirmed cases of lower airway disease (5 out of 8 patients; 63%), a finding that may point towards an association between lymphopenia and the severity of the 2009 H1N1 influenza in recipients of HSCT. Redelman-Sidi et al. 27 found that lymphopenia, in the setting of the 2009 H1N1influenza in cancer patients and HSCT recipients, was associated with hospitalization, but not with lower airway disease. Lymphopenia in the setting of seasonal influenza A infections in HSCT recipients, on the other hand, was found to be associated with an increased risk for the development of lower airway disease and mortality. 12, 14, 15 In our cohort, H1N1 infections were more commonly documented in recipients of allogeneic HSCT when compared with autologus HSCT, with attack rates of 13% vs 10%, respectively; a finding also observed by others. 12, 29 Allogeneic HSCT recipients have accounted for 53%, 33% and 50% of hospitalizations, patients with respiratory failure requiring mechanical ventilation and mortality cases in our cohort, respectively. A total of 12 patients in our series (31%) had GVHD (3 acute and 9 chronic GVHD); of those 3 were hospitalized and one developed respiratory failure and died. Nichols et al. 15 did not find any association between the donor type and the risk of seasonal influenza in recipients of HSCT. 15 In the same study, the presence of GVHD was not associated with an increased risk of influenza infection.
The timing of the 2009 H1N1 influenza in relation to the HSCT may have had an impact on the outcome and the severity of the 2009 H1N1 infections. In our cohort, though the majority (84.6%) of the 2009 H1N1 influenza occurred after the first 100 days of HSCT, yet the 3 patients who required mechanical ventilation in our study developed the 2009 H1N1 influenza rather early post transplantation (days þ 14, 78 and 139). In other words, 2/6 (33%) patients who acquired the 2009 H1N1 influenza at o100 days post-HSCT developed respiratory failure requiring mechanical ventilation vs 1/33 (3%) patients who developed the infection at 4100 days post transplantation.
Pediatric patients accounted for the majority of patients who developed the 2009 H1N1 influenza (62%) in our cohort, similar to the 2009 H1N1 influenza in normal hosts. 7, 26 They contributed to 53, 33 and 50% of patients who were hospitalized, required mechanical ventilation and those who died, respectively. Obesity was observed in 7 (18%) of the HSCT recipients with the 2009 H1N1 influenza in our cohort; 1 of them developed respiratory failure requiring mechanical ventilation, but none died. The mode of H1N1 acquisition was community-acquired in the majority of our patients (92%) while only three patients had health care-associated infections; the latter were the patients who subsequently developed respiratory failure and required mechanical ventilation. In all, 12 (31%) of the 2009 H1N1-infected patients were receiving immunosuppressive agents; of those 8 (67%) patients required hospitalization, 2 (17%) developed respiratory failure and 1 (8%) patient died. Redelman-Sidi et al., 27 on the other hand, have shown that immunosuppression in HSCT recipients may not be a substantial risk factor for the disease severity in the 2009 H1N1 influenza.
Previous reports have confirmed that the existence of comorbid conditions contribute to the severity of disease observed with the 2009 H1N1 influenza in normal subjects. 6, 7 Similarly in our cohort, comorbid conditions were present in a significant number of patients and could potentially have contributed to the worse outcomes seen in some of the patients; comorbid conditions were present in seven out of the eight (88%) patients with lower airway disease, in two out of three (67%) patients who required mechanical ventilation and in both patients who died.
There was a low rate of seasonal influenza vaccination in our HSCT patient population; only one patient with confirmed 2009 H1N1 influenza had received the seasonal influenza vaccination despite the fact that the vaccine was readily available to all patients free of charge. On the other hand, the 2009 H1N1 influenza vaccine was not available in Jordan at the peak of the pandemic and only became available late in December 2009.
Our study has several limitations; the number of tested and infected patients could have been slightly under estimated, as we could not confirm that all patients with symptoms presented to the center, particularly those who lived abroad. However, telephone follow-up of all patients confirmed that no significant events (for example, mortality) occurred in any of our patients outside the center during the study period. Similarly, the number of HSCT recipients diagnosed to have the 2009 H1N1 influenza may have been under estimated as the RT-PCR test might not detect all patients with influenza and serology might not be useful in HSCT patients. 31 In addition, optimization of antiviral dosing and duration was not possible in our study because of the unavailability of quantitative virology. Likewise, the exact number of patients who had lower airway disease could not be accurately estimated as not all patients had chest radiographs performed at the time of diagnosis. Moreover, this is a retrospective study in which previously set guidelines for admission were utilized; therefore, hospital admission might not have been an accurate estimate of the true severity of the disease. Finally, although some factors may have potentially contributed to the observed outcomes (for example, lymphopenia, immunosuppressive therapy and comorbid conditions), yet, because of the relatively small numbers of patients in our cohort, no solid conclusions could be drawn.
In summary, a less severe form of the 2009 H1N1 influenza infection was observed in the majority of our HSCT recipients. Early diagnosis and the prompt initiation of therapy may have played a role in lowering the mortality rates in our cohort of patients. However, a subset of patients required hospitalization and a few developed respiratory failure requiring mechanical ventilation; the majority of the latter subsequently died. Larger studies are required to further characterize and identify HSCT recipients at risk for worse outcomes.
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